openPR Logo
Press release

Gonorrhea Diagnostics Market Information - Forecast To 2023

07-03-2017 04:34 PM CET | Health & Medicine

Press release from: TMR - Research Reports

Gonorrhea Diagnostics Market Information - Forecast To 2023

Gonorrhea is a sexually transmitted disease caused by the bacterium Neisseria gonorrhoeae and can affect both genders. It is a common infection, especially among young people aged between 15 years to 24 years. According to the U.S. Centers for Disease Control and Prevention (CDC), gonorrhea is the second most commonly reported disease in the United States affecting approximately 800,000 people each year. In the United Kingdom, about 28,000 cases of gonorrhea are reported each year. Symptoms of gonorrhea in men encompass painful urination, swelling of testicles and pus discharge. In women, symptoms comprise excessive vaginal discharge, painful urination and abdominal pain. Complications include ectopic pregnancy, Pelvic Inflammatory Disease (PID) and Epididymitis. The incubation period for this disease also varies between men and women. In men, the symptoms occur between 2 to 14 days whereas in women it takes 7 days to 21 days to show symptoms. Astonishingly, about 50% of women have no symptoms in the early stage and during pregnancy it may infect the fetus during delivery.

Forecasting the Global Trends for Gonorrhea Diagnostics Market: http://www.transparencymarketresearch.com/gonorrhea-diagnostic-market.html

Diagnostic tests for gonorrhea include diagnostic imaging, flow cytometry, gel microdroplets, chromatography, artificial intelligence, liposomes, differential light scattering (DLS), molecular diagnostics and monoclonal antibodies test. Amongst these tests, molecular diagnostics is the most commonly employed diagnostic test. Molecular diagnostic tests include Nucleic Acid Amplification Tests (NAAT) that are highly sensitive for urine and swab tests, and are U.S. FDA approved. Over the years, there has been a substantial increase in the number of patients suffering from gonorrhea. Changing lifestyle and involvement of multiple sex partners has substantially boosted the market for gonorrhea diagnostics. In last few years, both Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) have reported instances of antibiotic resistant strains in patients. This further exaggerates the demand for early diagnostic kits or tests on a global scale. However inadequate infrastructure, limited trained laboratory personnel and lack of awareness in developing countries are among the major restraints to the global gonorrhea diagnostics market.

Geographically, the market is majorly driven by developed economic regions such as North America and Europe owing to presence of large number of point of care tests and high awareness among people with respect to sexually transmitted diseases. The U.S. Department of Health and Human Service recommend pelvic examination on an annual basis which also increases the growth prospects of this market. In 2013, the total number of new cases of gonorrhea diagnosed in genitourinary medicine (GUM) clinics in England was 29,291. This represented an increase of 15% compared to those diagnosed in 2012. However, in developing parts lack of appropriate knowledge and infrastructure has limited the growth prospects. Despite that, owing to increasing disposable incomes and changing lifestyles in developing regions, the market for gonorrhea is expected to have the fastest growth in Asia Pacific and Rest of the World regions. Recently in 2014, a new strain of gonorrhea known as A8806 was reported in Australia which is also multi-drug resistant. Such instances have raised concerns among researchers and government agencies owing to which, number of clinical trials in Asia Pacific region has drastically increased which will eventually boost the demand for diagnostic tests and kits.

Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1569

Some of the key players operating the global gonorrhea diagnostics market include Siemens AG, Tosoh Corporation, PerkinElmer, Inc., Abbott Laboratories, Beckman Coulter Inc., Ortho Clinical Diagnostics, F. Hoffmann-La Roche AG, bioMérieux and others.

About TMR

Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Gonorrhea Diagnostics Market Information - Forecast To 2023 here

News-ID: 606576 • Views: 324

More Releases from TMR - Research Reports

Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016. The global dental membrane and bone graft substitutes market is expected to
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period. By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment

All 5 Releases